Cargando…

UBE2C Induces Cisplatin Resistance via ZEB1/2-Dependent Upregulation of ABCG2 and ERCC1 in NSCLC Cells

OBJECTIVES: Cisplatin (DDP) is one of the most commonly used chemotherapeutic drugs for several cancers, including non-small-cell lung cancer (NSCLC). However, resistance to DDP eventually develops, limiting its further application. New therapy targets are urgently needed to reverse DDP resistance....

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Yan, Jin, Dan, Wang, Xiaohong, Du, Jing, Di, Weihua, An, Jiajia, Shao, Cuijie, Guo, Jiwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333017/ https://www.ncbi.nlm.nih.gov/pubmed/30693031 http://dx.doi.org/10.1155/2019/8607859

Ejemplares similares

Corrigendum to “UBE2C Induces Cisplatin Resistance via ZEB1/2-Dependent Upregulation of ABCG2 and ERCC1 in NSCLC Cells”
por: Wu, Yan, et al.
Publicado: (2020)

The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells
por: Guo, Jiwei, et al.
Publicado: (2018)

Retraction notice to ‘The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells’ [EBioMedicine 35 (2018) 204–221]
por: Guo, Jiwei, et al.
Publicado: (2021)

UBE2C, Directly Targeted by miR-548e-5p, Increases the Cellular Growth and Invasive Abilities of Cancer Cells Interacting with the EMT Marker Protein Zinc Finger E-box Binding Homeobox 1/2 in NSCLC
por: Jin, Dan, et al.
Publicado: (2019)

Retraction of “UBE2C, Directly Targeted by miR-548e-5p, Increases the Cellular Growth and Invasive Abilities of Cancer Cells Interacting with the EMT Marker Protein Zinc Finger E-box Binding Homeobox 1/2 in NSCLC”
por: Jin, Dan, et al.
Publicado: (2020)

Deregulation of UBE2C-mediated autophagy repression aggravates NSCLC progression
por: Guo, Jiwei, et al.
Publicado: (2018)

The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients
por: Obiedat, Hadeel, et al.
Publicado: (2018)

The predictive value of ERCC1 and p53 for the effect of panobinostat and cisplatin combination treatment in NSCLC
por: Cai, Yang, et al.
Publicado: (2015)

The antineoplastic drug metformin downregulates YAP by interfering with IRF-1 binding to the YAP promoter in NSCLC
por: Jin, Dan, et al.
Publicado: (2018)

The ZEB2‐dependent EMT transcriptional programme drives therapy resistance by activating nucleotide excision repair genes ERCC1 and ERCC4 in colorectal cancer
por: Sreekumar, Rahul, et al.
Publicado: (2021)

ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin
por: Tiseo, M, et al.
Publicado: (2013)

Retraction notice to ‘The antineoplastic drug metformin downregulates YAP by interfering with IRF-1 binding to the YAP promoter in NSCLC’ [EBioMedicine 37 (2018) 188–204]
por: Jin, Dan, et al.
Publicado: (2021)

Outcome Definition Influences the Relationship between Genetic Polymorphisms of ERCC1, ERCC2, SLC22A2 and Cisplatin Nephrotoxicity in Adult Testicular Cancer Patients
por: Zazuli, Zulfan, et al.
Publicado: (2019)

UBE2T regulates FANCI monoubiquitination to promote NSCLC progression by activating EMT
por: Zhang, Jiguang, et al.
Publicado: (2022)

ERCC1 and ERCC2 Variants Predict Survival in Gastric Cancer Patients
por: Li, Yangkai, et al.
Publicado: (2013)

Chicken xenobiotic receptor upregulates the BCRP/ABCG2 transporter
por: Xu, Ziyong, et al.
Publicado: (2022)

Analysis of ERCC1 and ERCC2 gene variants in osteosarcoma, colorectal and breast cancer
por: GÓMEZ-DÍAZ, BENJAMÍN, et al.
Publicado: (2015)

NOS1 upregulates ABCG2 expression contributing to DDP chemoresistance in ovarian cancer cells
por: Li, Xiaoxuan, et al.
Publicado: (2019)

ABCB1 and ABCG2 drug transporters are differentially expressed in non-small cell lung cancers (NSCLC) and expression is modified by cisplatin treatment via altered Wnt signaling
por: Vesel, M., et al.
Publicado: (2017)

Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines
por: Galetti, Maricla, et al.
Publicado: (2015)

TRIM58 Interacts with ZEB1 to Suppress NSCLC Tumor Malignancy by Promoting ZEB1 Protein Degradation via UPP
por: Shang, Rongxin, et al.
Publicado: (2023)

Association of ERCC1 and ERCC2 polymorphisms with colorectal cancer risk in a Chinese population
por: Ni, Min, et al.
Publicado: (2014)

Association of ERCC1 rs3212986 & ERCC2 rs13181 polymorphisms with the risk of glioma
por: Cui, Qing-ke, et al.
Publicado: (2014)

Norcantharidin reverses cisplatin resistance and inhibits the epithelial mesenchymal transition of human non-small lung cancer cells by regulating the YAP pathway
por: Jin, Dan, et al.
Publicado: (2018)

Norcantharidin reverses cisplatin resistance and inhibits the epithelial mesenchymal transition of human non-small lung cancer cells by regulating the YAP pathway
por: Jin, Dan, et al.
Publicado: (2021)

CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients
por: Park, S R, et al.
Publicado: (2011)

HP1γ Sensitizes Cervical Cancer Cells to Cisplatin through the Suppression of UBE2L3
por: Yi, Sang Ah, et al.
Publicado: (2020)

ERCC1 and ERCC2 Haplotype Modulates Induced BPDE-DNA Adducts in Primary Cultured Lymphocytes
por: Lu, Xiaobo, et al.
Publicado: (2013)

Contributions of UBE2C and UBE2S to meiotic progression of porcine oocytes
por: FUJIOKA, Yoshie A., et al.
Publicado: (2018)

The E2 ubiquitin-conjugating enzymes UBE2D1 and UBE2D2 regulate VEGFR2 dynamics and endothelial function
por: Critchley, William R., et al.
Publicado: (2023)

MEF2A transcriptionally upregulates the expression of ZEB2 and CTNNB1 in colorectal cancer to promote tumor progression
por: Xiao, Qing, et al.
Publicado: (2021)

Forkhead box K2 promotes human colorectal cancer metastasis by upregulating ZEB1 and EGFR
por: Du, Feng, et al.
Publicado: (2019)

Methyl-Cantharidimide (MCA) Has Anticancer Efficacy in ABCB1- and ABCG2-Overexpressing and Cisplatin Resistant Cancer Cells
por: Li, Yi-Dong, et al.
Publicado: (2020)

Predictive Value of Single Nucleotide Polymorphisms of ERCC1, XPA, XPC, XPD and XPG Genes, Involved in NER Mechanism in Patients with Advanced NSCLC Treated with Cisplatin and Gemcitabine
por: Mlak, Radosław, et al.
Publicado: (2018)

LncRNA SNHG1 upregulates ROCK2 to reduce cisplatin sensitivity of NSCLC cells by targeting miR-101-3p
por: Wei, Lei, et al.
Publicado: (2019)

KAT2A/E2F1 Promotes Cell Proliferation and Migration via Upregulating the Expression of UBE2C in Pan-Cancer
por: Lin, Shudai, et al.
Publicado: (2022)

Inhibition of ZEB1-AS1 confers cisplatin sensitivity in breast cancer by promoting microRNA-129-5p-dependent ZEB1 downregulation
por: Gao, Jin, et al.
Publicado: (2020)

ROCK2 Confers Acquired Gemcitabine Resistance in Pancreatic Cancer Cells by Upregulating Transcription Factor ZEB1
por: Zhou, Yang, et al.
Publicado: (2019)

HMGB2 upregulation promotes the progression of hepatocellular carcinoma cells through the activation of ZEB1/vimentin axis
por: Lu, Kai, et al.
Publicado: (2023)

Ets1 and ESE1 reciprocally regulate expression of ZEB1/ZEB2, dependent on ERK1/2 activity, in breast cancer cells
por: Sinh, Nguyen Duy, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_k5kgfbpvd3sqt31leu37bivrva